Mersana Therapeutics CEO Anna Protopapas' 2021 pay jumps 226% to $8.3M
Mersana Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 29, 2022
Mersana Therapeutics reported fiscal year 2021 executive compensation information on April 29, 2022.
In 2021, seven executives at Mersana Therapeutics received on average a compensation package of $3M, a 43% increase compared to previous year.
Average pay of disclosed executives at Mersana Therapeutics
Anna Protopapas, Chief Executive Officer, received $8.3M in total, which increased by 226% compared to 2020. 68% of Protopapas' compensation, or $5.6M, was in option awards. Protopapas also received $276K in non-equity incentive plan, $569K in salary, $1.8M in stock awards, as well as $7K in other compensation.
For fiscal year 2021, the median employee pay was $302,642 at Mersana Therapeutics. Therefore, the ratio of Anna Protopapas' pay to the median employee pay was 27 to one.
Timothy B. Lowinger, Senior Vice President, Chief Science and Technology Officer, received a compensation package of $3.1M, which increased by 134% compared to previous year. 61% of the compensation package, or $1.9M, was in option awards.
Brian DeSchuytner, Chief Financial Officer, earned $2.8M in 2021, a 190% increase compared to previous year.
Michael Kaufman, Former Chief Manufacturing Officer, received $2.5M in 2021, which increases by 107% compared to 2020.
Alejandra Carvajal, Chief Legal Officer, earned $2.2M in 2021.
Tushar Misra, Senior Vice President, Chief Manufacturing Officer, received $1.5M in 2021.
Arvin Yang, Chief Medical Officer, earned $869K in 2021, a 81% decrease compared to previous year.
Related executives
Anna Protopapas
Mersana Therapeutics
Chief Executive Officer
Brian DeSchuytner
Mersana Therapeutics
Chief Financial Officer
Alejandra Carvajal
Mersana Therapeutics
Chief Legal Officer
Timothy Lowinger
Mersana Therapeutics
Senior Vice President, Chief Science and Technology Officer
Michael Kaufman
Mersana Therapeutics
Former Chief Manufacturing Officer
Arvin Yang
Mersana Therapeutics
Chief Medical Officer
Tushar Misra
Mersana Therapeutics
Senior Vice President, Chief Manufacturing Officer
You may also like
Source: SEC filing on April 29, 2022.